Biomek®FX Enhanced Automated Sample Titration (BEAST): A Fully Automated Method of Titrating Compound for Counterscreen Assays

Printer Friendly

Juan B. Crespo1, José R. Tormo1, Julián Gorrochategui1, Pilar Sánchez1, Noemí Tabanera1, Genoveva Mateos1, Patricia Prieto1, Belen Pedraza1, Myriam Ruiz1, Neil Tiedeman2, Mike Van Vertloo2, Marc Goldstein2, Juan José Gragera2, Oscar Trabal2 and Fernando Peláez1

1. CIBE (Centro de Investigación Básica de España Merck Sharp & Dohme De España S. A. , Spain)
2. Beckman Coulter, Inc.

The overall objective regarding laboratory automation that pharmaceutical industries face is to achieve full automation of the main laboratory processes. This goal strives to reduce as many as possible human manual steps (and human error) while increasing the capacity and turn around time of current workflow processes.

One of the missions at CIBE is the centralization of a number of counterscreens used to assess potential toxicity and drug-drug interaction issues of chemical leads in a diverse range of therapeutic areas.

In the following compound workflow, BEAST supports the full automation of the counterscreen sample processing: from the initiation of Biomek® FX laboratory automation workstation variables to performing the final layout titrations.

Before BEAST:

• More than 10 different complex Biomek FX methods
• Additional source of errors and an extra time
• A long time and big efforts for including new titration Layouts in the systemMany incomplete final titration assay plates.
• Many manual steps without checking errors: Up 20 different assay conditions; Manual input of a high number of method variables; Manual replacement of labware and several manual pipetting steps

What is BEAST?

It is a complex system of several integrated tools driven by a Visual Basic (VB) application and is able to connect the CIBE LIMS with Biomek FX laboratory workstation without additional interface.

Click here for this poster (PDF)

Additional Information

• Biomek NX^P
• Biomek FX^P

* All trademarks are the property of their respective owners. Where applicable, the PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffmann-LaRoche, Ltd.

For Research Use Only; not for use in diagnostic procedures.

For comments or questions about T³ Update, please contact the T³ Editor.

Email this page to a colleague

Home | Products | Customer Support | Resource Center Employment | Our Company | Contact Us | Site Map  Privacy |  ©1998 - 2007 Beckman Coulter, Inc.